Mometasone

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mometasone

Quick Facts

Property Description
Active ingredient Mometasone Furoate
Forms Cream, Ointment, Nasal Spray, Inhalation Aerosol
Pharmacological class Corticosteroid (Glucocorticoid)
General purpose Anti-inflammatory and Anti-allergic effects
Origin Synthetic

Mometasone Furoate: Classification and Core Identity

Mometasone is the drug entity defined by its active ingredient, Mometasone Furoate, which is a highly potent synthetic corticosteroid. This compound is a halogenated glucocorticoid steroid ester, indicating a specific chemical structure engineered to maximize local activity. Mometasone Furoate belongs to the glucocorticoid pharmacological class, a category clinically recognized for its ability to modulate immune and inflammatory responses within target tissues. Its synthetic origin confirms that it is an engineered pharmaceutical compound, offering controlled potency and predictable performance when used topically, nasally, or by inhalation.

What Types of Mometasone Preparations are Available?

Mometasone Furoate is prepared in various pharmaceutical dosage forms optimized for localized treatment, a differentiating factor that allows targeted delivery. For topical administration intended for the skin, the substance is available as a cream, ointment, and lotion. For application directly to the nasal passages, it is formulated as a nasal spray in an aqueous suspension. Furthermore, preparations designed for inhaled use, such as a dry powder inhaler or inhalation aerosol, target the respiratory system. The primary therapeutic utility of this substance is based on its potent topical anti-inflammatory properties.

General Therapeutic Purpose and Anti-Inflammatory Action

The primary purpose of Mometasone is to provide powerful, targeted anti-inflammatory and anti-allergic effects at the site of application. Functionally, this highly active synthetic corticosteroid operates by suppressing the biological cascade that sustains both inflammation and allergic hypersensitivity. This action leads to the relief of symptoms such as swelling (edema), itching (anti-pruritic effect), and irritation. By curtailing these responses through its vasoconstrictive properties and general anti-inflammatory capacity, Mometasone addresses the underlying physical processes associated with allergic reactions and various inflammatory conditions.

Regulatory References

  1. MOMETASONE FUROATE cream (DailyMed)
  2. Mometasone Topical (MedlinePlus Drug Information)
  3. Mometasone Nasal Spray (MedlinePlus Drug Information)

What side effects are possible with Mometasone?

Official Safety Profile and Adverse Reactions

The safety profile for Mometasone Furoate, a synthetic corticosteroid, is structured by regulatory authorities to classify potential risks based on the route of administration (nasal, inhaled, or topical) and exposure time. Adverse reactions are grouped by frequency and the physiological system affected.

Frequency-Classified Effects

Common adverse reactions vary by formulation but often include localized effects. For the nasal spray, common effects documented in official labels are headache, epistaxis (nosebleeds), pharyngitis, and nasal irritation. Topical formulations commonly result in application-site reactions such as burning, stinging, and pruritus (itching).

Reactions classified as Rare or Not Known include more serious systemic or localized effects.

Systemic and Serious Adverse Reactions

Official documents list serious reactions related to potential systemic absorption, especially with long-term or extensive use. These include manifestations of HPA axis suppression (adrenal gland suppression) and signs of hypercorticism or Cushing’s syndrome. Ocular effects such as glaucoma and cataracts are also documented. In rare instances, immediate and severe allergic reactions, including anaphylaxis and angioedema, may occur.

Population and Duration Safety Notes

The risk of serious systemic effects is officially tied to the duration of use. Prolonged or excessive use is associated with a greater potential for these effects. For pediatric patients, regulatory documents include specific notes on the potential for reduced growth velocity with nasal or inhaled use. The official label restricts use in patients with conditions such as untreated localized infection (e.g., herpes simplex) or recent trauma at the application site.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information for Mometasone

Overdose with Mometasone is primarily associated with chronic overuse of the corticosteroid, particularly with inhaled or topical formulations.


Overdose Scope

Classification Official Regulatory Statements
Documented Overdose Presentations Overuse can lead to systemic effects such as hypercorticism and adrenal suppression (HPA axis suppression), which is identified as an important identified risk.
Exposure-Related Factors Chronic, long-term overuse is the main risk factor. However, acute ingestion of a large amount of a low systemic availability product (like the entire contents of a nasal spray bottle) is generally considered unlikely to cause clinically significant adverse events.
Population-Specific Overdose Note Pediatric patients may be more susceptible to systemic toxicity from equivalent doses, largely due to their larger skin surface area to body mass ratio for topical formulations.

Emergency Actions and Urgent Care

Condition Regulatory Statement on Action Required
Chronic Systemic Effects (Hypercorticism, Adrenal Suppression) Patients experiencing symptoms of chronic overuse may not require any more treatment than monitoring.
When Immediate Medical Help is Required Immediate medical help is recommended if a patient suffers from a sore nose and bleeding that is severe, or if new vision changes develop after starting the product.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile primarily through the risk of systemic corticosteroid effects, specifically the potential for adrenal suppression and hypercorticism, which are linked to chronic overuse of inhaled or topical forms. The official guidance indicates that monitoring may be sufficient for treating these chronic systemic effects. However, the need for immediate medical help is explicitly stated in connection with severe local symptoms, such as significant nose irritation or bleeding, or new adverse vision changes. The overall profile emphasizes the long-term, chronic nature of overdose risk over acute events for products with low systemic absorption.

Therapeutic Uses of Mometasone

Mometasone is applied across therapeutic domains involving inflammatory or irritative processes. It is commonly used to help with managing symptoms of conditions such as eczema, psoriasis, allergic rhinitis (seasonal or year-round), and persistent asthma. Mometasone is relevant for easing symptoms related to inflammatory or irritative states, such as redness, swelling, and noticeable itching (pruritus), along with respiratory symptoms like nasal congestion and frequent sneezing. It is applied in clinical settings that involve acute or unstable symptom patterns, supporting patients during difficult episodes.

“Mometasone is considered relevant for easing symptoms related to heightened physiological activity and chronic inflammation across the skin and airways.”

This symptomatic relief provides support that helps ease the overall symptom burden, and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Inflammation
Primary Benefit Supports the easing of overall symptom burden by targeting underlying inflammation.
Core Symptom Helps manage redness, swelling, and itching in the skin and airways.
Usage Context Commonly used for managing seasonal allergic symptoms and chronic inflammatory disease flares.

Eligibility and Restrictions for Use

Who can and cannot use Mometasone? - Official Regulatory Information

The eligibility to use Mometasone Furoate is strictly defined by regulatory authorities based on patient population, age, and existing medical conditions. Use is permitted for adults and older adults across all approved indications.


Contraindications and Absolute Exclusions

Mometasone is contraindicated in patients with a history of hypersensitivity to the active ingredient or any component of the specific preparation. Topical formulations must not be used on wounds, ulcerated skin, or in the presence of untreated skin infections (e.g., viral, fungal, bacterial). Nasal spray use is prohibited until healing is complete following recent nasal surgery, trauma, or septal ulcers.


Age-Related Eligibility and Restrictions

Formulation Minimum Age for Use (Typical) Regulatory Status of Younger Groups
Topical (Cream/Ointment) 2 years Not recommended for children <2 years (safety/efficacy not established).
Nasal Spray (Rhinitis) 2 or 3 years Safety and efficacy not established in infants below this age threshold.
Inhaled Aerosol 12 years Use for chronic rhinosinusitis with polyps is not established for patients under 18 years.

Physiological and Comorbidity Constraints

Use during pregnancy and lactation is generally not recommended unless the potential benefit outweighs the risk, per regulatory guidance; it is unknown if the drug is excreted in human milk. Caution is advised when using Mometasone in patients with active or quiescent tuberculous infections or systemic viral, bacterial, or fungal infections.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation structures the interaction profile of Mometasone Furoate primarily around metabolic processes and potential pharmacodynamic effects.


Pharmacokinetic Interactions and Exposure

The primary interaction involves drugs classified as strong metabolic inhibitors, which act on the CYP3A enzyme pathway responsible for Mometasone metabolism. Specific substances cited in regulatory information include cobicistat, ritonavir, and itraconazole. Co-treatment with these potent CYP3A inhibitors is expected to inhibit corticosteroid metabolism, resulting in a significant increase in systemic exposure to Mometasone Furoate. This combination is generally restricted and should be avoided unless the prescribing clinician determines the clinical benefit outweighs the increased risk of systemic corticosteroid side-effects.

The same metabolic principle applies to certain non-medicinal substances, as grapefruit or grapefruit juice is also documented to increase systemic exposure due to its inhibitory effect on CYP3A4.


Pharmacodynamic and Other Constraints

A pharmacodynamic interaction is documented with Central Nervous System (CNS) depressants, including alcohol. Concurrent use may cause additive reductions in alertness and functional impairment of CNS performance. Conversely, a clinical interaction study confirmed that co-treatment with loratadine resulted in no observed interaction. Official labeling does not contain mandatory timing rules that require doses of Mometasone to be separated by a specific number of hours from other substances.

Mechanism of Action

Mometasone is a synthetic glucocorticoid agonist that passively diffuses across the cell membrane into the cytoplasm of target cells. Its primary biological target is the cytosolic glucocorticoid receptor (GR). Mometasone binding to the inactive GR complex induces a conformational change, causing the drug-receptor complex to dissociate from chaperone proteins and translocate into the cell nucleus .

Within the nucleus, the activated GR-Mometasone dimer binds to specific DNA sequences known as Glucocorticoid Response Elements (GREs). This genomic mechanism modulates the transcription of various genes: it upregulates the transcription of anti-inflammatory proteins, such as lipocortin-1 (which inhibits phospholipase A2) and Glucocorticoid-Induced Leucine Zipper (GILZ). Simultaneously, it downregulates the transcription of genes encoding pro-inflammatory mediators, including cytokines, chemokines, and adhesion molecules.

Non-genomic action involves direct protein-protein interaction where the activated GR complex neutralizes pro-inflammatory transcription factors, such as NF-κB and AP-1, thereby preventing their signaling. The downstream cascades result in the systemic physiological consequence of diminished vascular permeability, reduced infiltration of leukocytes, and decreased production of pro-inflammatory eicosanoids.

Dosage and Administration Information

How to Use Mometasone: Administration Guidelines

Mometasone Furoate is administered via three approved routes: topical (skin), intranasal (nasal spray), or orally inhaled (inhaler). Following established dosing and procedural instructions is essential for proper use.


Official Dosing and Frequency

Administration Route Standard Adult Dosing (Typical) Key Frequency Instruction
Topical (Cream/Ointment) Apply a thin film once daily. Discontinue therapy once control is achieved.
Intranasal (Nasal Spray) 2 sprays (100 mcg) in each nostril once daily. Can be reduced to 1 spray per nostril for maintenance, or increased to twice daily (Total 400 mcg) for polyps.
Orally Inhaled Typically 220 mcg once daily in the evening. Maximum doses may be up to 880 mcg daily, administered twice daily.

Administration Requirements and Restrictions

Preparation and Procedural Steps

  • Nasal Spray: The device must be shaken well before each use. Prior to initial use, the pump must be primed (e.g., ten actuations) and reprimed if unused for more than one week.
  • Inhalation: After each dose from the inhaler, patients should be advised to rinse their mouth with water and spit out the contents without swallowing.
  • Missed Dose: If a dose is missed, it should be taken as soon as possible, but if it is near the time for the next dose, the missed dose should be skipped; do not double the dose.

Population and Site Rules

  • Pediatric Use: The intranasal dose for children aged 2 to 11 years is typically 1 spray (50 mcg) per nostril once daily. Topical use is not recommended in children under 2 years of age.
  • Topical Constraints: Apply only a thin film for the shortest necessary duration. Do not use the topical formulation on the face, underarms, or groin unless specifically directed by a healthcare provider, and do not use occlusive dressings over the treated area.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mometasone


Evidence Base for Allergic Rhinitis (Hay Fever and Year-Round Allergies)

Research has widely explored Mometasone nasal spray for contexts involving allergic irritative states. The evidence is predominantly derived from short-term, Randomized Controlled Trials (RCTs) and subsequent meta-analyses. Researchers monitored outcomes related to physical discomfort, including nasal congestion and sneezing, using standardized symptom scoring scales. These studies typically span two to four weeks.


Evidence Base for Persistent Asthma and Nasal Polyposis

For Persistent Asthma, Mometasone, in its inhaled form, was evaluated in a structured series of RCTs. These studies explored outcomes related to systemic or functional imbalance by examining objective measures of lung function, such as forced expiratory volume in one second (FEV1), and the frequency of asthma exacerbation events. For Nasal Polyposis, research examined outcomes linked to inflammatory states, including objective measures of polyp size and patient-reported nasal symptom scores over observation periods of one to four months.


Evidence Base for Inflammatory Skin Conditions

The topical formulations were studied for conditions like Eczema and Psoriasis using short-term, controlled clinical trials. Research focused on assessing physical measures of skin inflammation (redness and thickness) and patient-reported discomfort related to itching. The evidence structure for topical use is typical of short-term dermatological trials focusing on acute symptom assessment.


Evidence in Specific Patient Populations and Conditions

Research has evaluated Mometasone in children with adenoid hypertrophy, examining the measured change in adenoid size and associated obstructive nasal symptoms. The methodological quality of trials for adenoid hypertrophy was observed in some reviews to be inconsistent.


Long-Term Evidence and What Remains Uncertain

While extensive evidence exists, most core data focus on short-term symptom assessment. Data are still emerging for long-term effects related to the sustained observation of symptom patterns beyond six months. Comparative evidence remains limited for some newer therapeutic options, and the generalizability of findings is limited, as results apply only to the populations studied under specific trial conditions.

Key Studies & References Mometasone (Nasal) Drug Record and Indications

Frequently Asked Questions (FAQ)

Common questions about Mometasone (FAQ)


Q: What is the main difference between Mometasone and other steroid creams or nasal sprays?

Regulatory sources classify Mometasone Furoate as a highly potent synthetic glucocorticoid. This classification refers to its specific chemical structure, which is engineered to provide high anti-inflammatory power at the site of application compared to some other available steroids. This local potency is a key factor in its pharmacological profile.


Q: Can Mometasone cause weight gain according to patient discussions?

Regulatory documents state that systemic absorption of any corticosteroid, especially with prolonged topical use, can potentially lead to manifestations of Cushing's syndrome or hypercorticism. This condition is associated with symptoms that may include weight gain and high blood sugar levels (hyperglycemia). This risk is primarily linked to excessive or long-term systemic exposure.


Q: Are there any specific foods or drinks that should be avoided when using Mometasone?

The official product information specifies that the ingestion of grapefruit or grapefruit juice should be noted, as it is documented to increase the systemic exposure to Mometasone. This occurs because components in grapefruit can inhibit the CYP3A4 metabolic pathway responsible for breaking down the drug. No other specific foods are consistently noted in regulatory warnings.


Q: Is Mometasone safe to use long-term, based on general patient experience?

Official documents state that prolonged use increases the potential risk of serious systemic effects. These documented risks include adrenal gland suppression (HPA axis suppression), reduced growth velocity in children, and ocular conditions such as cataracts or glaucoma. Regulatory guidance suggests that use aligns with the duration specified by a healthcare provider.


Q: What happens if Mometasone is used for longer than the package suggests?

Using the medication for longer than suggested by a healthcare provider is officially associated with an increased risk of systemic side effects. This absorption can lead to signs of hypercorticism, including Cushing’s syndrome, which involves physical and metabolic changes. Official guidelines advise adherence to the shortest necessary duration.


Q: What are the most commonly reported side effects people complain about on forums?

The most common documented side effects vary by the product formulation used. For the nasal spray, this often includes headaches, nosebleeds (epistaxis), and pharyngitis, while topical forms most commonly cause local burning, stinging, or itching.


Q: Is it normal to feel a stinging or burning sensation when first using the nasal spray?

Burning and stinging sensations are common local effects reported for the topical cream or ointment. While the nasal spray commonly causes nasal irritation and dryness, stinging and burning are generally not listed as the primary adverse reactions for the nasal formulation. Regulatory information suggests persistent discomfort should be discussed with a clinician.


Q: What kind of research has been done on Mometasone use in children?

Research has evaluated Mometasone use in children for conditions such as adenoid hypertrophy. Official studies have also focused on monitoring the potential for reduced growth velocity in pediatric patients who receive the nasal or inhaled formulations, requiring specific regulatory advisories.


Q: Do studies suggest Mometasone is safe for pregnant or breastfeeding individuals?

Official documents indicate that there is very limited data on the use of Mometasone during pregnancy and lactation, and the potential risk to the fetus or infant is unknown. The official guidance specifies the drug is intended for use only if the potential benefit is determined to outweigh the potential risk.


Q: Does Mometasone cream thin the skin, and what do users say about it?

Official labels and postmarketing reports for the topical formulations list skin atrophy (thinning) as a documented adverse reaction. This risk is primarily associated with prolonged or extensive use of the topical products and is a known risk of potent corticosteroids.


Q: What is the typical duration of a course of treatment with Mometasone?

The duration of treatment often depends on the formulation and condition being treated. Topical use on the body is typically limited to a maximum of three weeks. Clinical trials for conditions like nasal polyps were conducted over a four-month period.


Q: What is the shelf life of Mometasone once the packaging is opened?

The official storage requirements for the nasal spray specify that it must be discarded 75 days after the first opening, regardless of the amount of product remaining. The specific in-use shelf life for other formulations is not consistently specified across public regulatory documents.


Q: Can Mometasone be used if someone has a fungal infection in the area of application?

Regulatory guidance states that the nasal spray should not be used in the presence of a pre-existing bacterial, viral, or fungal infection in the nasal passages. Likewise, topical creams or ointments must not be used on untreated skin infections, including fungal infections, in the area of application.


Q: Can Mometasone be used by individuals with glaucoma?

Glaucoma is documented as a serious adverse reaction, especially with long-term systemic absorption. The official label indicates that patients should discuss visual symptoms with a clinician, as referral to an ophthalmologist may be considered due to the potential for increased intraocular pressure.


Q: Do people use Mometasone for treating conditions other than allergies or asthma?

Mometasone has approved uses and has been studied for several conditions beyond seasonal allergies and asthma. These indications include allergic rhinitis, persistent asthma, nasal polyposis, eczema, and psoriasis.


Q: Is Mometasone known by a different name in other countries?

Yes, Mometasone Furoate is sold under several different brand or trade names across various international regions. The generic substance, Mometasone Furoate, is the same regardless of the trade name.


Q: How quickly should someone expect Mometasone nasal spray to start working?

Some relief from symptoms may begin to improve within 12 hours to two days after the first dose of the nasal spray. However, official information notes that it may take between one to two weeks of regular use to feel the full therapeutic benefit.


Q: Why is Mometasone sometimes used by athletes or for sports-related issues?

Mometasone is officially classified as a glucocorticoid, which is a class of substances generally prohibited in-competition by organizations like the World Anti-Doping Agency (WADA). Use of the drug during competition typically requires a valid Therapeutic Use Exemption (TUE), which is granted for specific medical conditions.


Q: Are there any known issues with taking Mometasone while also having diabetes?

Regulatory guidance specifies that plasma glucose monitoring is required more closely upon the start of Mometasone treatment for individuals with diabetes. This precaution is advised due to the potential for systemic absorption to cause increases in blood sugar levels.


Q: Can using Mometasone make you feel shaky or anxious?

While shakiness or anxiety are not listed as common side effects, mood changes and dizziness can be signs of more serious systemic effects. These effects are rare and may relate to adrenal gland problems that can occur with long-term systemic absorption.


Q: Are there any studies looking at Mometasone's effect on eye pressure?

Postmarketing reports list increased intraocular pressure, glaucoma, and cataracts as possible effects related to corticosteroid use. The official label indicates that patients should report any visual symptoms for clinical review.


Q: Is there a rebound effect or worsening of symptoms if Mometasone is stopped suddenly?

Sudden discontinuation of long-term topical treatment with potent glucocorticoids may cause a rebound phenomenon. This effect is documented as possibly leading to dermatitis with redness, stinging, and burning in the treated area.


Q: Are there any general precautions for using Mometasone with heart conditions?

Regulatory documents advise caution when the combination inhaler product is used by patients with cardiovascular disorders. These conditions can include coronary artery disease, cardiac arrhythmias, and hypertension.


Q: Can Mometasone affect hormone levels in the body?

Systemic absorption of Mometasone can produce reversible suppression of the hypothalamic-pituitary-adrenal (HPA) axis. This HPA suppression affects the body's natural ability to produce corticosteroid hormones.


Q: Is Mometasone known to cause issues with teeth or gums?

Official instructions state that rinsing the mouth with water and spitting out the contents without swallowing is required after using the inhaler. This is intended to reduce the risk of localized oral or pharyngeal side effects, such as thrush (candidiasis), which can affect the mouth and throat.


Q: Is there a maximum amount of time Mometasone should be used without a break?

The official duration of use is defined based on the formulation and site of application. For topical use, treatment may be limited to a maximum of three weeks on the body. Clinical trials for nasal polyposis studied the drug's use over a four-month period.


Q: Does Mometasone affect the immune system in a noticeable way?

Mometasone is a synthetic glucocorticoid that works to suppress the biological cascade that sustains both inflammation and allergic hypersensitivity. This mechanism means the drug profoundly modulates the local immune and inflammatory response at the site of application.


Q: What are the common reasons people discontinue using Mometasone?

Official documentation indicates that contacting a clinician for re-evaluation is appropriate if symptoms are not controlled after a specified period of time. Other reasons for clinician contact include persistent local irritation or the development of visual disturbances.


Q: What are the signs that Mometasone might not be working for someone?

Lack of symptom control over the recommended duration is a key sign to look for. For nasal polyps, official documentation indicates that if symptoms are not controlled after a specified treatment period (e.g., five to six weeks), re-evaluation by a clinician is recommended.


Q: Do the side effects of Mometasone improve over time or get worse?

Official product information notes that some mild side effects, such as a burning or stinging feeling from the cream, may stop happening after using the medication for a few days. However, the duration or progression of other adverse effects is not universally stated and depends on the specific reaction.

How should Mometasone be stored and disposed of?

Storage and Disposal Requirements for Mometasone

Mometasone Furoate preparations must be stored according to specific regulatory conditions to maintain their integrity and effectiveness.

Official Storage Conditions

Condition Type Requirement
Temperature Range Store at controlled room temperature between 20°C to 25°C (68°F to 77°F).
Environmental Rule Do not freeze (especially for nasal spray). Protect the product from light.
Container Rule Keep the medicine stored in the original container.
Child Safety Must be kept out of the sight and reach of children.

Stability and Disposal

The stability of the nasal spray is limited after initial use; it must be discarded within 75 days of the first opening, regardless of the remaining product. All unused or expired Mometasone must be disposed of in accordance with local regulations and must not be thrown away via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mometasone found in:

A-Z Index: